8-K 1 doc1.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Event Requiring Report: May 28, 2003 ADVANCED PLANT PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 000-28459 59-2762023 ------------- ----------------------- ------------------ (State of (Commission File Number) (IRS Employer) Incorporation) Identification #) 43 West 33rd Street, New York, New York 10001 -------------------------------------------- (Address of Principal Executive Offices) (212) 695-3334 ---------------------------------------- (Registrant's telephone number, including area code) ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE On May 28, 2003, the Registrant entered into an agreement with Tele-V, LLC., a marketing company with in-house expertise in purchasing, manufacturing and marketing consumer products, and the ability to execute print and broadcast media buys. According to the terms of the agreement, Tele-V, LLC has the exclusive right to purchase a minimum of 100,000 bottles, through July 2003 of APPI's patented cholesterol reducing dietary supplement, Lo-Chol, for resale. In exchange for awarding Tele-V, LLC the exclusive rights for the marketing and distribution of Lo-Chol, Tele-V, LLC has agreed to bear all costs associated with the marketing, designs, and distribution etc. of Lo-Chol, including a significant commitment of media buys. Tele-V, LLC will produce and air a Lo-Chol radio commercial within 90 days of this agreement, followed by the production and airing of an infomercial on Lo-Chol within 120 days. Pursuant to the Agreement, Tele-V shall purchase a minimum of $2,000,000 worth of purchase orders per year after the date of the first purchase order. On June 3, 2003, the Registrant put out a press release covering this information. EXHIBITS N/A SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. By: /s/ David Lieberman --------------------------------- David Lieberman President Date: June 16, 2003 2